Azenta (NASDAQ:AZTA – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its peers? We will compare Azenta to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, risk, dividends and profitability.
Valuation and Earnings
This table compares Azenta and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Azenta | $621.70 million | -$166.99 million | -13.30 |
| Azenta Competitors | $2.27 billion | $55.87 billion | -7.71 |
Azenta’s peers have higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Azenta has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Azenta’s peers have a beta of 0.94, meaning that their average stock price is 6% less volatile than the S&P 500.
Profitability
This table compares Azenta and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -26.86% | 1.41% | 1.15% |
| Azenta Competitors | -487.52% | 78.70% | -13.00% |
Analyst Ratings
This is a summary of recent recommendations for Azenta and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| Azenta Competitors | 958 | 3198 | 5533 | 179 | 2.50 |
Azenta currently has a consensus price target of $47.60, suggesting a potential downside of 1.15%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.82%. Given Azenta’s peers stronger consensus rating and higher possible upside, analysts clearly believe Azenta has less favorable growth aspects than its peers.
Summary
Azenta peers beat Azenta on 8 of the 13 factors compared.
About Azenta
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
